Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 5Other solid neoplasm 3Gynecologic 3Other hematologic neoplasm 2Lymphoid 2Genitourinary 2Tumor-Agnostic 1Thoracic 1Plasma cell 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Metastatic Castration-Resistant Prostate Cancer 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × sapanisertib × Genitourinary × Clear all
NCT03097328 2024-04-29

Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Dana-Farber Cancer Institute

Phase 2 Completed
39 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell

NCT02091531 2019-11-21

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
9 enrolled 10 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡